Skip to content
EntityQ25091391· pop 10· linked from 764 articles

darolutamide

Sign in to save

Also known as ODM-201, BAY-1841788

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

Key facts

Drug.Verifiedfields
verified
Drug.verifiedrevid
459978482
Drug.image
ODM-201.svg
Drug.image_class
skin-invert-image
Drug.width
250
Drug.image2
Darolutamide molecule ball.png
Drug.image_class2
bg-transparent
Drug.width2
250
Drug.tradename
Nubeqa
Drug.MedlinePlus
a619045
Drug.licence_EU
yes
Drug.DailyMedID
Darolutamide
Drug.pregnancy_AU
X
Drug.routes_of_administration
By mouth
Drug.class
Nonsteroidal antiandrogen
Drug.ATC_prefix
L02
Drug.ATC_suffix
BB06
Drug.legal_AU
S4

via Wikipedia infobox

~15 min read

Encyclopedic overview

23 sections
Contents
  • Medical uses
  • Available forms
  • Contraindications
  • Side effects
  • Overdose
  • Interactions
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Absorption
  • Distribution
  • Metabolism
  • Excretion
  • Variability
  • Chemistry
  • History
  • Society and culture
  • Generic names
  • Brand names
  • Availability
  • Research
  • References
  • External links

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

Side effects of darolutamide added to castration may include fatigue, asthenia, pain in the arms and legs, and rash. Darolutamide is a nonsteroidal antiandrogen (NSAA), and acts as a selective antagonist of the androgen receptor (AR). It has been referred to as a second- or third-generation NSAA.

Excerpted from Wikipedia’s “darolutamide” article, available under the CC BY-SA 4.0 licence.

Available in 9 languages

via Wikidata sitelinks · CC0